Premaitha Health PLC Director's dealing and share option issue (0439D)
October 05 2018 - 2:00AM
UK Regulatory
TIDMNIPT
RNS Number : 0439D
Premaitha Health PLC
05 October 2018
Premaitha Health PLC
("Premaitha," the "Company" or the "Group")
Director's dealing and share option issue
Manchester, UK - 5(th) October 2018: Premaitha (AIM: NIPT), a
leading international molecular diagnostics group, announces that
it has been informed yesterday by Barry Hextall, a director of the
Company, that 100,000 ordinary shares in the Company were purchased
yesterday by Mr Hextall at a price of 10 pence per share. Following
the acquisition, Mr Hextall's beneficial interest in the Company is
432,518 ordinary shares, representing 0.1 per cent of the Company's
issued share capital as notified on 1 October 2018.
In addition, further to the appointment of Hayden Jeffreys to
the Board announced 3 October 2018, Mr Jeffreys has been awarded
share options over 3,000,000 ordinary shares, exercisable at 10
pence per share subject to the existing Company scheme rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Premaitha Health PLC Tel: +44 (0)16 1667 1053
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0)20 7220 0500
Geoff Nash / Matthew Radley (Corporate
Finance)
Tim Redfern (Corporate Broking)
Vigo Communications Tel: +44 (0)20 7390 0234
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests.
The Group's current primary focus is on non-invasive prenatal
tests (NIPT) for pregnant women - an emerging, multi-billion dollar
global market - although the Group intends to expand its product
range into other areas of clinical genetics.
Premaitha's first product, the IONA(R) test was launched in 2015
as the first CE-IVD NIPT test in Europe. It enables laboratories
and healthcare practitioners to offer a complete CE-marked NIPT
system in-house. The IONA(R) test is performed on a maternal blood
sample - which contains traces of fetal DNA - and estimates the
risk of a fetus being affected with Down's syndrome or other
genetic conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening solution that operates
on the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Since May 2018, the Group has traded as Yourgene Health outside
of Europe (but remains as Yourgene Bioscience in Taiwan),
reflecting the increased scope of the business in other areas of
clinical genetics further to reproductive health; but maintains the
Premaitha Health brand within Europe.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- ---------------------------------------------------------------------------------------------
a. Name (i) Barry Hextall
(ii) Hayden Jeffreys
--------------------------------------------------------------
2 Reason for notification
----------------------------- --------------------------------------------------------------
a. Position/Status (i) Chief Financial Officer
(ii) Group Commercial Director
----------------------------- --------------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
----------------------------- --------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------------
a. Name Premaitha Health plc
-----------------------------
b. LEI 213800UUIT8BZE7QEH33
----------------------------- --------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- ---------------------------------------------------------------------------------------------
a. Description of (i) Ordinary shares of 0.10p each
the financial (ii) Options over 3,000,000 ordinary shares
instrument, type of 0.10 pence each, exercisable at 10p
of instrument
ISIN: GB00BN31ZD89
Identification
Code
----------------------------- --------------------------------------------------------------
b. Nature of the (i) Purchase of ordinary shares
transaction (ii) Issue of share options to purchase
3,000,000 ordinary shares of the Company
----------------------------- --------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
----------------------------- -------------------
(i) 10p (i) 100,000
(ii) 10p (ii) 3,000,000
------------------- ----------------------------
d. Aggregated information
- Aggregated Volume (i) 100,000
(ii) 3,000,000
- Price
(i) 10p
(ii) 10p
----------------------------- --------------------------------------------------------------
e. Date of the transaction 4 October 2018
----------------------------- --------------------------------------------------------------
f. Place of the transaction London Stock Exchange
----------------------------- --------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKQDNPBDDBKK
(END) Dow Jones Newswires
October 05, 2018 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024